In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hawaii Biotech, Inc.

http://www.hibiotech.com/

Latest From Hawaii Biotech, Inc.

Zika Vaccines Might Be Approved By 2020

Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.

Vaccines Research & Development

A Snapshot Of Neglected Disease Drug Development: Dengue Fever

Neglected diseases are gaining a higher profile in Big Pharma drug development programs. Research on a vaccine for dengue fever has been ongoing for decades, and a few candidates could finally be nearing late-stage trials.

BioPharmaceutical Asia Pacific

Sanofi In Phase III Trials For Dengue Vaccine, Offering Emerging Market Potential

Sanofi already generates a substantial share of its revenue from emerging markets, but developing the first dengue vaccine would have significant impact on emerging market revenue, perhaps as early as 2015.

Asia Pacific Clinical Trials

ASEAN issues call for dengue action as cases rise

The 10 member countries of ASEAN (the Association of Southeast Asian Nations) have agreed to collaborate more closely on the prevention, surveillance and treatment of dengue amid a steady rise in the incidence of the disease.

Infectious Diseases Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register